Steven Fruchtman
President at TRAWS PHARMA, INC.
Net worth: 75 540 $ as of 2024-03-30
Profile
Steven M.
Fruchtman is currently the Director at the Bone Marrow & Cancer Foundation, Inc. He is also the President & Chief Scientific Officer-Oncology at Traws Pharma, Inc. Previously, Dr. Fruchtman held positions as the Director of Stem Cell Transplantation at The Mount Sinai Hospital, Medical Director-Hematology & Oncology at Ortho Biotech Products LP, and Senior Director-US Clinical Development at Novartis Pharmaceuticals Corp.
He also served as the Chief Medical Officer at Spectrum Pharmaceuticals, Inc. from 2011 to 2013 and as the Vice President-Clinical Development at Allos Therapeutics, Inc. from 2009 to 2011.
Additionally, he was the Chief Medical Officer at Syndax Pharmaceuticals, Inc. from 2013 to 2014 and the Chief-Stem Cell Transplantation Program at Icahn School of Medicine at Mount Sinai.
Dr. Fruchtman completed his undergraduate studies at Cornell University and obtained his doctorate degree from New York Medical College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
TRAWS PHARMA, INC.
0.36% | 2024-03-13 | 74,792 ( 0.36% ) | 75 540 $ | 2024-03-30 |
Steven Fruchtman active positions
| Companies | Position | Start |
|---|---|---|
| TRAWS PHARMA, INC. | President | 2018-06-20 |
Bone Marrow & Cancer Foundation, Inc.
 Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Steven Fruchtman
| Companies | Position | End |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2014-05-31 |
| SPECTRUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2013-06-30 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 2010-12-31 |
The Mount Sinai Hospital
 The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | - |
Training of Steven Fruchtman
| Cornell University | Undergraduate Degree |
| New York Medical College | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| TRAWS PHARMA, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
The Mount Sinai Hospital
The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Health Services |
Ortho Biotech Products LP
 Ortho Biotech Products LP Pharmaceuticals: MajorHealth Technology Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | Commercial Services |
- Stock Market
- Insiders
- Steven Fruchtman
